Skip to content

Study · Not a test of the peptide alone · 2020

2 results

Pharmacological Treatment for Obesity in Adults: An Umbrella Review.

Khalil H, Ellwood L, Lord H, Fernandez R

The Annals of pharmacotherapy20 Jan 2020Cited by 27 (Europe PMC)

PMID31958967 (opens in a new tab)DOI10.1177/1060028019898912 (opens in a new tab)PepBankPUB-31958967
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone2

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

  1. 01HumanNot a test of Liraglutide aloneSystematic reviewEfficacy outcome

    In adults with obesity, the pooled pharmacotherapies in the reviews (liraglutide, orlistat, naltrexone-bupropion) reduced weight compared with placebo.

    In plain wordsIn adults with obesity, three weight-loss drugs taken together reduced weight more than placebo. This is not a result for liraglutide alone.

    Peptide
    Liraglutide
    Outcome
    DecreaseWeight reduction versus placebo (pooled drugs)
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Body weight · Metabolic and weight

    Source sentences

    Summary
    The results indicate that the pharmacotherapies reduced weight when compared with placebo.
    1 context sentence
    Summary · context
    Nine systematic reviews involving three pharmacotherapies, liraglutide, orlistat, and naltrexone-bupropion were identified.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

  2. 02HumanNot a test of Liraglutide aloneSystematic reviewSafety outcome

    In adults with obesity, the reviews discussed gastrointestinal adverse effects (diarrhea, vomiting, nausea) related to orlistat and liraglutide together.

    In plain wordsIn adults with obesity, reviews discussed stomach and bowel side effects of orlistat and liraglutide together. Results are not split by drug.

    Peptide
    Liraglutide
    Outcome
    IncreaseGastrointestinal adverse effects (orlistat and liraglutide pooled)
    Study

    n: not reported in source

    Outcome group
    Gastrointestinal adverse events · Gastrointestinal

    Source sentences

    Summary
    All reviews discussed the presence or risk of gastrointestinal adverse effects including diarrhea, vomiting, and nausea related to orlistat and liraglutide.
    1 context sentence
    Summary · context
    Nine systematic reviews involving three pharmacotherapies, liraglutide, orlistat, and naltrexone-bupropion were identified.

    In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 11:11 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:05 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.